Aspire Biopharma Issues Shareholder LetterESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson.
Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of MembersESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.® (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 's lineup of 50mg sublingual caffeine stick packs will now be available to an expansive community of health-conscious gym members.
MicroCap Stocks: GLE, ADMQ, ASBP, BRQL Gaining Attention Across AI Infrastructure, Aerospace, Biotech and Industrial MarketsA new group of emerging microcap stocks is gaining investor attention as themes tied to artificial intelligence infrastructure, aerospace defense, biotechnology innovation, and industrial manufacturing continue driving market momentum. Investors are increasingly focusing on Global Engine Group Holding Limited, ADM Endeavors Inc., Aspire Biopharma Holdings Inc., and Dynamic Aerospace Systems Corporation as each company aligns with rapidly expanding sectors attracting global capital and strategic partnerships.
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split RatioESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".
Aspire Biopharma Announces $5.0 Million Share Repurchase ProgramESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS).
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 RevenueESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered into a Letter of Intent (LOI) to acquire Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. Management of DCS will be bolstered by the addition of a team from Lakewood & Company with more than 100 years' collective experience within the automotive industry.
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales DirectorESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health & Fitness (HFA) Show, scheduled for March 16-18 at the San Diego Convention Center.
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon SponsorshipBUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Aspire Biopharma Regains Full Compliance with Nasdaq Listing RequirementsCompany achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of RecordESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement - has named ChicExecs as its public relations agency of record.
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®.
Aspire Biopharma Announces the Appointment of New Member to Its Board of DirectorsNew independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq RequirementsESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has entered into a securities purchase agreement on February 6, 2026 (the "Securities Purchase Agreement") with select institutional and accredited investors (collectively, the "Investors") for the purchase and sale of up to 26,250 shares of Series A Convertible Preferred Stock (each, a "Preferred Share" and collectively, the "Preferred Shares"), at a purchase price of $800 per Preferred Share. The Preferred Shares are convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), representing aggregate gross proceeds to the Company of up to $21.0 million, before deducting placement agent fees and other offering expenses (the "Offering").
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementCompany achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition SummitESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a proprietary sublingual caffeine supplement today announced its participation at The Sports & Active Nutrition Summit USA, scheduled for February 18-20 in San Diego, CA. Aspire will feature its flagship caffeine product, BUZZ BOMB™, at the event.
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California DistributionESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB™, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets.
